Skip to content
Clinical Trials – home
Therapeutic area

Endocrine disorders – page 39

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Diabetic retinal oedema+4

Not recruiting

Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Y-mAbs Therapeutics A/S

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on RZ358 for Treating Congenital Hyperinsulinism in Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years
  • Substances:Anti-(Insulin Receptor) Human Monoclonal Antibody
  • Sponsor:Rezolute Inc.

Hypoparathyroidism

Not recruiting

Study on the Effectiveness and Safety of Eneboparatide, Calcitriol, and Calcium Carbonate for Patients with Chronic Hypoparathyroidism

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Effects of Finerenone on Kidney Health in Patients with Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Universitaetsklinikum Erlangen AöR

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Study on the Safety and Effectiveness of TP-102 for Treating Diabetic Foot Infections in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:F1245/05
  • Sponsor:Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.

Androgenetic alopecia

Not recruiting

Study on the Effectiveness and Safety of Oral Minoxidil for Women with Androgenetic Alopecia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Minoxidil
  • Sponsor:Industrial Farmaceutica Cantabria S.A.
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin
  • Sponsor:Uppsala Universitet

Study on Heart Health in Type 2 Diabetes Patients Using Semaglutide and Dapagliflozin Combination

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Odense University Hospital

Study on Digoxin and Sodium Iodide (123 I) for Patients with Advanced Non-Medullary Thyroid Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Stichting Radboud universitair medisch centrum

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.